1103862-13-0 Usage
Description
5-Acetylpyridine-3-boronic acid pinacol ester is a boron-containing reagent with a unique chemical structure that plays a significant role in the synthesis of various compounds, particularly in the pharmaceutical industry. It is characterized by its ability to form stable complexes with other molecules, making it a valuable intermediate in the development of new drugs and therapeutic agents.
Uses
Used in Pharmaceutical Industry:
5-Acetylpyridine-3-boronic acid pinacol ester is used as a synthetic intermediate for the development of pyrimidine derivatives. These derivatives act as inhibitors of 6-phosphofructose-2-kinase, an enzyme that plays a crucial role in cancer cell metabolism. By inhibiting this enzyme, the pyrimidine derivatives can potentially disrupt the energy supply of cancer cells, leading to their growth inhibition and eventual death.
Used in Cancer Treatment:
5-Acetylpyridine-3-boronic acid pinacol ester is used as a key component in the synthesis of compounds that target cancer cells. The resulting pyrimidine derivatives have shown potential in the treatment of various types of cancer by disrupting the energy metabolism of cancer cells, thereby inhibiting their growth and proliferation. This makes it a promising candidate for the development of novel anticancer drugs.
Check Digit Verification of cas no
The CAS Registry Mumber 1103862-13-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,0,3,8,6 and 2 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1103862-13:
(9*1)+(8*1)+(7*0)+(6*3)+(5*8)+(4*6)+(3*2)+(2*1)+(1*3)=110
110 % 10 = 0
So 1103862-13-0 is a valid CAS Registry Number.
1103862-13-0Relevant articles and documents
ALDOSTERONE SYNTHASE INHIBITORS
-
Paragraph 0348, (2014/11/11)
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2. R3, R4, R5, R6, R7, W, Y, m and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
